Osteoporosis treatment

What is it?

The primary objective of anti-osteoporotic therapy is to reduce the risk of fragility fractures (vertebral, femoral, wrist) and increase bone mineral density. The treatment is based on modification of unhealthy lifestyles (stop smoking and alcohol use, physical activity appropriate to age, proper and balanced diet), adequate supplementation with calcium and vitamin D. Depending on the clini+B5:I28cal picture and the presence of osteoporosis fractures, it is possible to use an anabolic therapy (e.g. teriparatide) or an antiresorptive therapy (bisphosphonates, denosumab).

When is this procedure indicated?

After an adequate anamnesis collection, the examination should take into account the patient's biochemical, radiological and clinical parameters. Antiresorptive or anabolic treatment is indicated in subjects at high fracture risk.

How is it performed?

  • Calcium carbonate or citrate daily orally.
  • Vitamin D orally in refractory doses.
  • Bisphosphonates orally (weekly or monthly) or intravenously (zoledronic acid annually).
  • Denosumab subcutaneously every 6 months.
  • Teriparatide subcutaneously every day for up to 24 months.


  • Gastric or gastrointestinal upset (frequent with bisphosphonates by mouth).
  • Alterations in calcium metabolism (possible hypocalcemia predominantly with zoledronic acid and/or denosumab; possible hypercalcemia and hypercalciuria with teriparatide).
  • Osteonecrosis of the jaw (very rare with bisphosphonates and/or denosumab).
  • Atypical femur fracture (very rare with bisphosphonates and/or denosumab).

Are you interested in receiving the treatment?

Contact us and we will take care of you.